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Background: Cancer patients are at risk of developing blood clots in their veins - venous thromboembolism
(VTE) - which often takes the form of a pulmonary embolism or deep vein thrombosis. The risk increases with
advanced disease. Evidence based treatment is low molecular weight heparin (LMWH) by daily subcutaneous
injection. The aim of this research is to explore the barriers for doctors in the UK when diagnosing and treating
advanced cancer patients with VTE.
Method: Qualitative, in-depth interview study with 45 doctors (30 across Yorkshire, England and 15 across South
Wales). Doctors were from three specialties: oncology, palliative medicine and general practice, with a mixture of
senior and junior staff. Framework analysis was used.
Results: Doctors opinions as to whether LMWH treatment was ethically appropriate for patients who were
symptomatic from VTE but at end of life existed on a shifting continuum, largely influenced by patient prognosis.
A lack of immediate benefit coupled with the discomfort of a daily injection had influenced some doctors not to
prescribe LMWH. The point at which LMWH injections should be stopped in patients at the end of life was
ambiguous. Some perceived ‘overcaution’ in their own and other clinicians’ treatment of patients. Viewpoints were
divergent on whether dying of a PE was considered a “good way to go”. The interventionalism and ethos of
palliative medicine was discussed.
Conclusions: Decisions are difficult for doctors to make regarding LMWH treatment for advanced cancer patients
with VTE. Treatment for this patient group is bounded to the doctors own moral and ethical frameworks.
Keywords: Venous thromboembolism, Heparin, Low-molecular-weight, Palliative care, Qualitative research,
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People living with cancer often develop blood clots in their
veins - venous thromboembolism (VTE) and have a six-
fold risk of developing VTE compared to those without
cancer [1] The risk increases as the cancer progresses; one
survey demonstrated evidence of deep vein thrombosis
(DVT) in over 50% of admissions to a specialist palliative* Correspondence: Laura.sheard@york.ac.uk
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reproduction in any medium, provided the orcare unit [2]. VTE most commonly takes the form of a
pulmonary embolism (PE) or DVT. A PE is an obstruction
of the pulmonary artery (or branch of it) leading to the
lung, by a blood clot. DVT is usually a blood clot in the
veins of the lower leg or thigh. A range of symptoms may
be caused by a PE from none at all, to severe breathless-
ness or death, and a DVT may be asymptomatic, or can
cause distressing lower limb pain and swelling [3]. A DVT
can precipitate a PE, whereby the blood clot travels from
the leg to the lungs.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(“blood thinning”). Recommended, evidence based treat-
ment to prevent recurrence or extension of VTE for patients
with cancer is low molecular weight heparin (LMWH) by
daily subcutaneous injection for three to six months. This is
preferential to oral warfarin which is the most common
treatment for a blood clot in people without cancer. War-
farin is less effective in preventing extension or recurrence
of a clot than LMWH and may also carry a higher risk of
bleeding complications in cancer patients than LMWH, es-
pecially for those undergoing chemotherapy, those at risk of
intracranial or metastatic bleeding, and those with advanced
disease. UK registry [4] data showed that long term LMWH
was not routinely prescribed by clinicians for cancer
patients. We conducted a study to explore the barriers to
recommended practice in this clinical area.
Management decisions in those with advanced disease
but who are not imminently dying can be difficult [5].
Some areas of palliative medicine may be viewed as a par-
ticularly ethically fraught when it comes to medical deci-
sion making, especially where prognostication is difficult.
Recent commentators have discussed the limitations of
end of life treatment [6], the end of life decision making
process for dementia patients [7] and the quality of ethical
guidelines at the end of life [8]. The four prima facie princi-
ples of medical ethics – autonomy, beneficence, non-
maleficence & justice [9] – allow us a lens through which
to view decisions made in this area of medicine, VTE treat-
ment in advanced cancer patients. Decisions in the area of
VTE management may represent a tension between the
principles of beneficence (do good) and non-maleficence
(minimise harm). In this paper we discuss a subset of the
findings from a study conducted to explore the barriers to
recommended practice for patients with VTE and cancer.
The theme of ‘appropriateness’ was identified by doctors
who were interviewed during the study as a major part of
their decision-making process when managing people with
VTE and advanced cancer.Method
The wider study on which this paper is based was con-
ducted in two phases. In phase one, 46 doctors were
recruited and took part in a ‘think aloud’ exercise which
aimed to understand how doctors make decisions regarding
advanced cancer patients with VTE. In phase two, 45 doc-
tors participated in an in depth interview to explore the bar-
riers present for doctors when diagnosing and treating this
patient group. This paper focuses on the theme of ‘appropri-
ateness’ which arose from the phase two interview data.
NHS Research Ethics approval was obtained in March
2010 and Research Governance approval from 7 NHS
Trusts and 3 Welsh Health Boards was granted between
July and September 2010.Participants
In depth interviews were conducted with 45 UK doctors
(30 across Yorkshire, England and 15 in the South of
Wales). Fieldwork took place between September 2010 and
January 2011. For phase one of the study, doctors at con-
sultant and medical director level were identified by regis-
ters in the public domain: hospital websites for oncologists,
the current Hospice Directory for palliative medicine clini-
cians and Primary Care Trust websites for GPs or the web-
sites of individual GP practices. Doctors at SpR or ST grade
were identified through Deanery lists. Potential participants
were invited by a letter on behalf of the research group, sent
by mail or email. Doctors who had taken part in phase one
were e-mailed and asked if they would be interested in par-
ticipating in stage two (on which this paper is based). Thirty
two out of the 45 participants were purposively sampled
and then recruited in this manner. The majority of the rest
were recruited by snowball sampling, seeking to maximize
variation in the sample.
The doctors selected for this study were purposively
sampled on their occupation specialty and grade as these
are the pivotal variables for the wider study. This consisted
of: oncologists (15 in England, 5 in Wales), palliative medi-
cine doctors (10 in England, 5 in Wales) and GPs (5 in each
site). Oncologists were recruited from two large teaching
hospitals, two oncology hospitals and two district general
hospitals. Palliative medicine doctors worked in some of
the hospitals mentioned above and a wide range of hospices
(some participants had a dual hospital/hospice role). GPs
worked across North Yorkshire, South Glamorgan, Mid
Glamorgan & Gwent. Variation within specialties was maxi-
mized by ensuring a mixture of senior and junior staff. This
allowed for opinion based on the differing experiences of
doctors at different stages in their career and training to be
accessed. Participants ranged in age from 28 to 58 years
with 26 women and 19 men. They practised across a geo-
graphically broad area in both sites, covering all four ridings
of Yorkshire and a large section of South Wales.
Data collection
The initial topic guide focussed on the barriers and facilitators
to practice around VTE and cancer. Most of the interviews
began with the broad question “can you tell me what you
think the barriers are to the diagnosis and treatment of cancer
patients with VTE?” Questioning about the barriers to prac-
tice for VTE in cancer patients centred on: anticoagulation;
diagnosis & treatment of VTE; logistical, clinical, institutional
or attitudinal issues; positive facilitators to good practice.
Questioning was adaptive to the responses of the participants.
The topic guide was restructured and amended through-
out the fieldwork as new themes emerged. Interviews were
largely conducted at the participants’ place of work al-
though a minority of participants were interviewed in their
home. All participants provided written, informed consent
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20 and 70 min. The interview was taped with a digital re-
corder and the digital file was transcribed.Analysis
We used Framework Analysis [10] whilst maintaining the
notion that analysis is “constantly iterative” [11]. Framework
Analysis begins from the aims and objectives of the study
yet is inherently grounded in the opinions and experiences
of the population studied. DD and LS independently scruti-
nised the same six transcripts, which were selected for max-
imum variation. The initial coding framework was devised
after comparison of resulting draft frameworks, discussion
and subsequent revision. LS and HP coded all the interviews
and reached full agreement on coding after four interviews,
thereafter coding independently all subsequent interviews.
All data were inputted into Atlas.ti which allowed us to
effectively sort the data. LS conducted the final two stages of
analysis: charting, mapping and interpretation. This creative
process involves defining concepts and mapping polarities
to identify the range and extent of a phenomenon. Themes
were written up describing the similarity and variation be-
tween participant’s experiences.
The themes reported in this paper are only one portion
of the wider study. Other pertinent themes were: logistical
& organisational issues, VTE risk assessment tools, patient
& disease specific factors and knowledge, evidence &
experience.
Results
This paper emphasises the agenda of the doctors inter-
viewed - treatment decisions for them were less concerned
with the choice between LMWH and warfarin (as most
were found to be using LMWH) and more concerned with
whether treatment itself could be considered appropriate
for patients with advanced cancer. Doctors held widely dis-
crepant opinions as to whether LMWH injections should
be administered to patients who were symptomatic from
VTE but only had weeks or days to live.
Continuum of appropriateness
The opinions of the participants in relation to what they
considered appropriate for advanced cancer patients with
VTE existed on a continuum. Some doctors had strong
viewpoints that patients should not receive anticoagulation
(or be investigated for VTE) if they were believed to be in
the last few weeks of life whereas doctors who were at the
opposite end of the continuum believed that it was the right
of the patient to be treated and rejected notions they per-
ceived as paternalistic. Few participants believed that patients
at the end of life should always be treated for VTE as the
doctors decisions often continually shifted based on context
and – most importantly – patient wishes and prognosis.Many doctors wondered if it was “fair” to give a patient a
daily subcutaneous injection of LMWH in the last few weeks
of life. Doing so was said to worsen the quality of life in the
short time which the patient had left due to the assumed pain
and subsequent bruising by administering the injection into a
patient’s abdomen. This fed into debates about whether
patient’s lives were being prolonged unnecessarily as a result
of anticoagulation. A phrase used by a few participants was
“doing more harm than good” with a sometimes associated
sense of futility. A senior GP in England outlines this:
If you’ve got terminal cancer, something is going to
kill you and for the quality of life of your last few days
does it matter if you live several hours less because
you’ve got a thromboembolism than having your last
few days dreadful because people have been sticking
needles in you on a regular basis (England, ID 14).
In the middle of the continuum, a range of factors were
said to influence a doctors decision as to whether they con-
sidered it appropriate to treat with LMWH injections. The
pivotal variable appeared to be the prognosis of the patient
with treatment said to be largely unbeneficial at the end of
life due to the fact that in the short time left, patient’s
symptoms may not be ameliorated by LMWH injections.
A few participants explained how there was a lack of im-
mediate benefit from a LMWH injection, especially for a
DVT. This lack of immediate benefit contrasts with some
other medical situations in which a patient would receive
an injection and sometimes influenced clinicians, as this
palliative medicine consultant in England discusses:
Normally in a hospice context, when you give an
injection it’s for pain relief or nausea and you’re
expecting an immediate return on what you do and so
you off-set the discomfort for the patient and the staff
member of giving and receiving the injection by the
immediate reward of symptom relief. With low
molecular weight heparin for venous
thromboembolism, some of the archaic attitude is,
“well either it’s happened anyway and if it happens
again, it’s a nice way to go”, compounded by the fact
that the patient isn’t receiving any immediate comfort
from the injection and, [the nurses say] “oh look very
bruised” (England, ID 3)
Whereas treatment for a DVT may see no immediate
benefit, LMWH injections can relieve breathlessness in
people with PE and was seen as a situation in which some
doctors considered it appropriate for dying patients. A pal-
liative medicine consultant in Wales explains this:
If you’ve got sudden central crushing chest pain and
you can’t breathe and you’re scared stupid and your
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and I think that’s one of the things that probably
directs me that it’s an acute presentation and you’re
treating people, not just because you thinking you’re
adding days to their life but also it hurts a lot and for
lots of people you would, if you identify and treat
them then it is symptom management as well as time
and also in terms of quality because if you’ve had
loads of thrombus showers, then in functional terms,
even if you don’t die today, you will have functional
impairment because of breathlessness because of your
post thrombotic complications in your lungs really, so
it’s symptom control. (Wales, ID 13)
One of the main difficulties in following the debate is that,
the term ‘end of life’ (sometimes used interchangeably with
the term ‘dying’) was clearly understood in a variety of ways
by the participants. Some used the term interchangeably
with “dying now”. However, most described end of life as
the last hours or few days but a minority talked about it as a
much longer timescale of at least weeks. This has implica-
tions for the stage at which doctors would perceive LMWH
injections as unsuitable as the defining point of ‘end of life’
was so variable and it was therefore difficult to pinpoint a
general consensus. The point at which – or even whether -
LMWH injections should be stopped when someone was
coming towards the end of life was perceived as a difficult
judgement to make. This was wrapped in the tension as to
whether dying patients should be “interfered” with and even
whether palliative medicine intervenes too much in this in-
stance, as this palliative medicine consultant in Wales states:
I think doing nothing a lot of the time is good
practice and you shouldn’t be meddling just because
there is a treatment available. . .If they’re becoming
comatosed, if they’re not drinking, if they’re not
taking oral medication, then what are we doing
jabbing them? You’ve got to be thinking about the
time limit of it [life expectancy] and is it helpful to do
that? (Wales, ID 4)
Some participants questioned whether they were too over-
cautious in relation to making decisions about treatment.
Over-caution was a contradictory concept: some perceived
themselves – and others – as being too cautious to stop the
injections (usually for fear of the patient becoming breath-
less) whilst others would have already stopped the injections
to spare the patient what they felt was unnecessary interven-
tion. A palliative medicine consultant in England outlined
both sides of this contradiction:
I think because we look after people who have got
quite advanced disease and you know their prognosis
is short and what you don’t want to do is makeanything worse because you would just feel
awful. . .So for example if you think someone may or
may not have a DVT but they are otherwise quite
poorly but comfortable, if they are not getting a lot of
symptoms about that then it’s being overcautious
about do I interfere with the rest of the quality of
their life when they are not that symptomatic. And I
think you can forget that they might just go and have
a big PE and then they would be far more
symptomatic. And then you think well if they are
going to die relatively shortly, as long as they have a
really big PE and go really quickly then it is not going
to be too awful a thing. Your mind goes round all
these things and then you think, well what if they just
have a moderate sized PE and they are really
breathless but don’t die (England, ID 8)
A senior palliative medicine doctor also in England
describes how she felt other staff were being too over-
cautious when it came to stopping the injections:
I think it’s easy to start something [LMWH injections]
and then it become inappropriate and doesn’t get
stopped. . . Lots of patients come to their last few days
of life who are still on it and there can be quite a lot of
anxiety about stopping it. You know, junior doctors
agonise over stopping it, even if the patient is on the
Care Pathway in the last 48 h, why are their agonising?
I think the perception of the risk of stopping it is
amplified to what it should be (England, ID 6)
Ethical decisions surrounding investigation largely mir-
rored those of treatment. It was considered inappropriate by
a minority to subject the patient to what was said to be the
distressing journey to hospital (and possible inpatient stay in
a setting ill-equipped to manage complex symptoms in
people with advanced cancer) if they were at the end of life.
If the doctor had already decided not to treat the patient
then there was said to be very little point in confirming or
excluding a PE or DVT diagnostically. However, it did ap-
pear that in these unwell patients, logistical difficulties with
regard to accessing diagnostic services had a more dispro-
portionate effect on the decision not to investigate and treat
than if the patient had a better performance status.A good way to die?
Debate was present about whether dying from a PE could
be considered a good way to die – “a good way to go” and
opinions were put forward which both supported and
opposed this idea. Some of these opinions have already
been reflected in the quotations outlined previously, as dis-
cussion about whether a PE was a good way to die was
prevalent throughout the interviews. A previous qualitative
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be a quick, painless way to die [12] but evidence [13] sug-
gests death is rarely instantaneous and can be distressing
and painful. Many of the doctors working in hospices
described how the idea of a PE being a good way to die
was often prevalent amongst nursing staff, as this palliative
medicine registrar in England explains:
I suppose in their [nurses] mind they see a PE as a
sudden event which takes them [patients] away and
that is a good thing. Maybe it is a lack of experience
of seeing that actually PEs aren’t always fatal and they
can actually be debilitating rather than killing
somebody. I suppose it is a paternalistic approach of
wanting to care for that patient and protect them
from harm and hoping that is the way they are going
to go but it is not under our control to do that. So I
think it is a slightly misheld belief based on a little bit
of experience but not enough experience. It’s
transferring their views onto that patient. . .I think it
is just that they care so strongly and they get so
involved with our patients and quite rightly you get to
know them so well that you get protective over them
and they don’t want us to stab them with needles
which will make them bleed if actually in their mind
they might die peacefully in their sleep. But
unfortunately it is not always that way (England, ID 2)
When it came to doctors’ own opinions on this matter,
an oncology consultant and a palliative medicine con-
sultant - both from Wales - outlined their contrasting
stances respectively:
Do you want to be treating people with VTE and PE and
do you want to be running around and looking for it in
cancer patients with very bad prognosis and very little
time to live? No. Should I be giving them all low
molecular weight heparin injections into their stomach
when they are dying? No, I don’t think so. Maybe that is
why this VTE business was [previously] not looked for in
patients with advanced cancer because we are thinking
that their prognosis is quite limited and some would
argue that is a reasonable way to go. You have cancer
and you are in a lot of pain and suffering and all this and
then if it is the PE that is going to do it in the end, so
what? Are we harming the patient? I don’t think we are
harming the patient (Oncology consultant, Wales, ID 7)
I’m actively looking to treat anybody who has a PE or
DVT because obviously my perspective is that I see
people with either horribly unmanaged DVTs or who
become very, very breathless with what I presume is a
PE and I don’t see that as a good way to die, so I’m
very hot on wanting to pick them up, diagnose themand I know I will be picking up and diagnosing only a
proportion of what’s probably there but I’m very keen
to encourage patients to have the treatment (Palliative
medicine consultant, Wales, ID15)
Hospice ethos
Debate existed as to whether patients should just be cared
for (“tucked up”) at the end of life and whether investiga-
tion itself represents an instance of over-medicalisation.
With regards to treatment as well as investigation, doctors
who worked in hospices often commented on the medical
culture of the hospice they worked in. In some more trad-
itional hospices, VTE was not a common clinical consider-
ation and not actively investigated or treated in keeping
with the ethos that dying patients should have the least
intervention possible, as this palliative medicine registrar
in England describes:
The most recent hospice that I’ve worked in was very
traditional, old style hospice and everything you did
got challenged. I think they very much felt that we
should almost be tucking the patients up and letting
them die, you know, starting the syringe driver, “we’re
not doing anything more than that.” Anything more
than that they felt was cruel to the patient and
actually doctors just taking over and doing things that
they wanted to do rather than in the best interests of
the patient and they felt like that quite strongly. So to
get a scan [at the hospital] for a patient there, they
really would have to justify it with everyone. Whereas
if I’d worked in other places they would be, “fine we’ll
phone up and we’ll organise transport for you and
we’ll sort this bit out” (England, ID 1)
A non-interventionist ethos had angered and frustrated
a few participants. One palliative medicine registrar made
the comparison between how pneumonia would not be
ignored, whereas VTE sometimes is.
Discussion
This paper has explored the ethical decisions which doctors
face for advanced cancer patients with VTE, at the end of
life. Whether an action could be considered “appropriate”
for this group of patients was a major part of doctors’ deci-
sion making strategies. However, defining what is appropri-
ate and what is not seems to be intrinsically related to the
individual viewpoints of different doctors, which can be
demonstrated by the divergent viewpoints which were held
for the same issue. This can clearly be seen when partici-
pants discussed the dilemma as to whether dying of a PE is
considered a good or bad way to die with contradicting per-
sonal opinions of two doctors, both at consultant level, with
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frame used to support their opposite conclusions. Inherent
in the views of those opposed to LMWH for patients at the
end of life may be an implicit paternalism given that patient
choice is more firmly aligned with the viewpoint of offering
LMWH in order to prevent or control the symptoms of a
fatal PE. This has direct implications for patient care as two
similar patients seen by different doctors may be subject to
polarised clinical opinions on administering LMWH, which
potentially entails consequences for patient choice and au-
tonomy, controlling symptoms and also life expectancy.
The majority of doctor’s decision making strategies are
guided by individual patient context and can be placed on
a shifting continuum that pays attention to the complex
benefits and burdens of giving treatment for patients near
the end of life. General Medical Council guidelines on
treatment towards the end of life state:
. . .It may be of no overall benefit to provide potentially
life-prolonging but burdensome treatment in the last
days of a patient’s life when the focus of care is
changing from active treatment to managing the
patient’s symptoms and keeping them comfortable [14]
But this obfuscates the fact that LMWH for some patients
may be partly or wholly for the purposes of symptom man-
agement. This was most often the case to prevent severe
breathlessness becoming worse by preventing further PE,
thus allowing the symptom to settle. But it was coupled with
the burden that an immediate return – within hours - may
not be seen with daily injections. This represents an ethical
dilemma in itself and it is here where we can see the tension
between the principles of beneficence (do good) and non-
maleficence (minimise harm). Some doctors may lean to-
wards beneficence upon witnessing patients becoming
breathless. However, there is anecdotal concern that a
LMWH injection is too invasive and distressing for patients
with advanced cancer, both due to the pain of the injection
and also the subsequent bruising, especially in the last few
days of life. This may sway some doctors towards the
principle of non-maleficence based on the potential distress
of a subcutaneous injection. However, in a study which
looked at treatment injections, a daily LMWH injection was
found to be acceptable to patients with advanced cancer
[15]. Given this evidence, it could be argued that clinicians
who withhold LMWH injections because they do not want
to submit the patient to the perceived discomfort of the
physical act of the injection are making a moral decision
which may run contrary to that of the patient’s own choice.
However, this argument has to be put into context of clini-
cians witnessing patients in distressing circumstances and
compassionately not wanting to inflict additional burden on
their patient when the immediate cessation of symptoms
may not happen and the patient is imminently dying.Many of the doctors interviewed for this study stated that
their medical decision making generally would depend on
patients’ wishes but as the empirical qualitative data shows,
doctors did not discuss this in any detail with regard to the
central theme of this paper; starting or stopping LMWH
injections. It may appear incongruous that physicians
would not talk about involving patients and their families
in the decision making process for LMWH injections.
However, it is clear that in this research this topic was not
explicitly discussed by the doctors interviewed. This is not
to state that doctors believe involving patients or families is
unimportant or irrelevant but that the research team found
no evidence either way to support or refute this notion.
The main limitation of this study is concerned with
how representative the sample of self selecting doctors
interviewed can ever be in a specialist area. Participants
who agreed to an in depth interview may have been
those who had a particular interest in advanced cancer
patients and VTE – this may have been especially true
of palliative medicine doctors and oncologists who see
these patients on a frequent basis. Potential participants
may have opted not to take part in the research if they
felt their level of knowledge about cancer and VTE was
not significant and that they may have incurred embar-
rassment as a result of this. This is a general problem in
some areas of qualitative health research - and not spe-
cific as such - to our area of interest, but many of the
participants were familiar with the principal investigators
of the project via their clinical work.
The term "end of life" was deliberately not concretely
defined during the interviews to allow for doctors to dis-
cuss their own decision making with reference to
patients on this spectrum of advanced disease. We be-
lieve this approach has borne rich data about the ambi-
guity in clinical decision making for this patient group
and we did not use a formal measure of performance
status as that is not usual routine clinical practice in the
UK across all settings.
There is little formal guidance or literature to help these
clinicians with difficult decisions in the treatment of VTE
for this group of patients. Whereas guidance on pain, agi-
tation, nausea & vomiting, cardiopulmonary resuscitation,
hydration & nutrition, ventilation and sedation at the end
of life is available [16], no formal management guidelines
exist for VTE specific to patients with advanced progres-
sive cancer although Noble et al. have made recommenda-
tions based on the literature applied, where possible, to
the palliative care population [5]. Although there is a large
body of literature about end of life decision making,
regarding a range of medical, consent and capacity issues,
little has been written about the ethical decisions which
doctors make regarding VTE in advanced cancer patients.
No standardised practice or formal guidance is available to
help doctors make these challenging and complicated
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individualistic and contextual nature of VTE treatment at
the end of life.
Conclusions
From the findings of this study, we can see how decisions
are difficult for doctors to make for advanced cancer
patients towards the end of life with VTE. These decisions
are nuanced and often placed on a shifting continuum
which takes into account both explicit but also subtle fac-
tors. The concept of “appropriateness” represents major
elements of the decision making process which doctors en-
gage with regarding this patient group, with little in the
way of guidance to help doctors. Opinion on whether an
action is considered “appropriate” can be polarised, even
for doctors at the same grade and within the same spe-
cialty. This leads to implications for patient care, autonomy
and life expectancy. LMWH as symptom control some-
times complicates matters further and can be an ethical di-
lemma in itself. In this paper, we have showed that
treatment for VTE in this patient group is intrinsically
bound to the doctors own moral and ethical framework.
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